AR123206A1 - Terapia génica - Google Patents
Terapia génicaInfo
- Publication number
- AR123206A1 AR123206A1 ARP210102238A ARP210102238A AR123206A1 AR 123206 A1 AR123206 A1 AR 123206A1 AR P210102238 A ARP210102238 A AR P210102238A AR P210102238 A ARP210102238 A AR P210102238A AR 123206 A1 AR123206 A1 AR 123206A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- acid construct
- vector according
- cell
- host cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063064431P | 2020-08-12 | 2020-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123206A1 true AR123206A1 (es) | 2022-11-09 |
Family
ID=77655525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102238A AR123206A1 (es) | 2020-08-12 | 2021-08-11 | Terapia génica |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2022131322A1 (cg-RX-API-DMAC7.html) * | 2020-12-17 | 2022-06-23 | ||
| IL312340A (en) * | 2021-10-28 | 2024-06-01 | UCB Biopharma SRL | Nucleic acid constructs, viral vectors and viral particles |
| GB202216168D0 (en) | 2022-10-31 | 2022-12-14 | UCB Biopharma SRL | Route of administration |
| WO2024163823A1 (en) * | 2023-02-02 | 2024-08-08 | Shape Therapeutics Inc. | Tissue-specific enhancers for regulating transcription |
| JP2026509301A (ja) * | 2023-03-14 | 2026-03-17 | ユーシービー バイオファルマ エスアールエル | 遺伝子治療 |
| CN121335978A (zh) * | 2023-06-16 | 2026-01-13 | 舒泰神(北京)生物制药股份有限公司 | 一种人源MeCp2启动子及其用途 |
| WO2025213097A1 (en) * | 2024-04-05 | 2025-10-09 | The Children's Hospital Of Philadelphia | Novel gene therapy constructs for stxbp1 haploinsufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110045536A1 (en) * | 2007-12-21 | 2011-02-24 | Novartis Ag | Mammalian expression vector |
| CN104583402A (zh) * | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| CN114717264A (zh) * | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| AU2015349759B2 (en) * | 2014-11-21 | 2022-01-06 | The University Of North Carolina At Chapel Hill | Aav vectors targeted to the central nervous system |
| JP6754361B2 (ja) * | 2014-12-16 | 2020-09-09 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 若年型バッテン病のための遺伝子療法 |
| CA3016314A1 (en) * | 2016-03-02 | 2017-09-08 | Julianne REIDERS | Therapy for frontotemporal dementia |
| TWI601821B (zh) * | 2016-04-15 | 2017-10-11 | 中央研究院 | 治療神經發展性疾病 |
| WO2020081490A1 (en) * | 2018-10-15 | 2020-04-23 | Voyager Therapeutics, Inc. | EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM |
-
2021
- 2021-08-11 MX MX2023001701A patent/MX2023001701A/es unknown
- 2021-08-11 AR ARP210102238A patent/AR123206A1/es unknown
- 2021-08-11 AU AU2021325717A patent/AU2021325717A1/en active Pending
- 2021-08-11 PH PH1/2023/550145A patent/PH12023550145A1/en unknown
- 2021-08-11 BR BR112023002374A patent/BR112023002374A2/pt unknown
- 2021-08-11 US US18/021,005 patent/US20230295657A1/en active Pending
- 2021-08-11 CA CA3188748A patent/CA3188748A1/en active Pending
- 2021-08-11 TW TW110129603A patent/TWI902867B/zh active
- 2021-08-11 EP EP21766127.1A patent/EP4196171A1/en active Pending
- 2021-08-11 PE PE2023000142A patent/PE20230914A1/es unknown
- 2021-08-11 CN CN202180056525.5A patent/CN116113441B/zh active Active
- 2021-08-11 WO PCT/EP2021/072365 patent/WO2022034130A1/en not_active Ceased
- 2021-08-11 JP JP2023509770A patent/JP7860958B2/ja active Active
- 2021-08-11 KR KR1020237007287A patent/KR20230044506A/ko active Pending
- 2021-08-11 IL IL300294A patent/IL300294A/en unknown
-
2023
- 2023-01-09 ZA ZA2023/00378A patent/ZA202300378B/en unknown
- 2023-01-16 CO CONC2023/0000444A patent/CO2023000444A2/es unknown
- 2023-02-10 CL CL2023000419A patent/CL2023000419A1/es unknown
- 2023-03-08 EC ECSENADI202316688A patent/ECSP23016688A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023000444A2 (es) | 2023-01-26 |
| EP4196171A1 (en) | 2023-06-21 |
| IL300294A (en) | 2023-04-01 |
| JP7860958B2 (ja) | 2026-05-18 |
| AU2021325717A1 (en) | 2023-03-02 |
| CL2023000419A1 (es) | 2023-07-21 |
| CA3188748A1 (en) | 2022-02-17 |
| PE20230914A1 (es) | 2023-06-02 |
| TW202221018A (zh) | 2022-06-01 |
| US20230295657A1 (en) | 2023-09-21 |
| WO2022034130A1 (en) | 2022-02-17 |
| CN116113441A (zh) | 2023-05-12 |
| PH12023550145A1 (en) | 2024-03-18 |
| KR20230044506A (ko) | 2023-04-04 |
| BR112023002374A2 (pt) | 2023-03-21 |
| CN116113441B (zh) | 2026-06-09 |
| JP2023537980A (ja) | 2023-09-06 |
| ZA202300378B (en) | 2024-04-24 |
| TWI902867B (zh) | 2025-11-01 |
| ECSP23016688A (es) | 2023-04-28 |
| MX2023001701A (es) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEAP202416053A (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| Kim et al. | Recombinant Vaccinia virus-coded interferon inhibitor B18R: Expression, refolding and a use in a mammalian expression system with a RNA-vector | |
| ATE531808T1 (de) | Lentivirale triplex-dna und vektoren sowie rekombinante zellen mit lentiviraler triplex-dna | |
| CY1110349T1 (el) | Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη | |
| ATE89006T1 (de) | Expression von menschlichem proapolipoprotein a- 1. | |
| ATE198354T1 (de) | Protein aufspüren auf hiv virion auf basis von hiv-1 vpr fusionmolekulen | |
| FI932678A7 (fi) | Alfaviruksiin perustuvia DNA-ilmentämissysteemejä | |
| EP1054683A4 (en) | MODIFIED HEAT SHOCK PROTEIN / PEPTIDEANT COMPLEX | |
| Stansell et al. | Gp120 on HIV-1 virions lacks O-linked carbohydrate | |
| DE60024100D1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
| KR100469936B1 (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
| CL2023000419A1 (es) | Terapia génica utilizando construcciones de ácidos nucleicos que comprenden secuencias promotoras de la proteína 2 | |
| EP0977862B8 (en) | Ricin-like toxin variants for treatment of cancer, viral or parasitic infections | |
| NO20063556L (no) | HIV gp41 HR2-avledede syntetiske peptider og deres anvendelse ved behandling av human mangel pa immunitet mot virus | |
| Tang et al. | Recombinant adenoviruses displaying matrix 2 ectodomain epitopes on their fiber proteins as universal influenza vaccines | |
| Kropp et al. | Identification of the cleavage domain within glycoprotein G of herpes simplex virus type 2 | |
| Bowles et al. | Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques | |
| ES2673972T3 (es) | Formas solubles de la glicoproteína G de los virus hendra y nipah | |
| ES2118242T3 (es) | Vacunas anti virus de la inmunodeficiencia felina (fiv). | |
| DOP2024000204A (es) | Composiciones y métodos para la prevención y el tratamiento de la infección por el virus de la rabia | |
| ATE457349T1 (de) | Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen | |
| BR0016289A (pt) | Vìrus sentinela i do vìrus da hepatite | |
| FR2829774B1 (fr) | N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications | |
| RU2345138C2 (ru) | ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК р-ВМС-gag(A)-hum ДЛЯ ЭКСПРЕССИИ БЕЛКА р55 ВИЧ-1 В КЛЕТКАХ ЭУКАРИОТ | |
| BR0316722A (pt) | Constructos genéticos e composições compreendendo rre e cte e usos destes |